Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

III development as part of a collaboration between sanofi-aventis and Regeneron.

S-1 is a novel oral fluoropyrimidine that combines three investigational agents: tegafur, a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine) which inhibits dihydropyrimidine dehydrogenase enzyme; and oteracil (potassium oxonate), a gastrointestinal side effect corrector. The Phase III data to be presented evaluate the addition of cisplatin to S-1 in advanced gastric cancer. S-1 is marketed in Japan by Taiho for a variety of indications including gastric cancer. Sanofi-aventis is leading the development of the compound outside of Japan and in some Asian countries.

TroVax(R) is a therapeutic cancer vaccine developed in collaboration with Oxford BioMedica. It targets the tumor antigen 5T4, broadly distributed in a wide range of solid tumors. The presentation will include new data from two Phase II trials of TroVax(R) in renal cancer.

Finally, the first outcomes of the innovative program "My Child Matters," a unique humanitarian pediatric cancer initiative in developing countries co- sponsored by sanofi-aventis and the International Union Against Cancer (UICC), will be presented.

Details on the key studies to be presented at the meeting during podium presentations and poster discussions are as follows:

Eloxatin(R) (oxaliplatin injection) clinical studies:

Abstract # 4007 - Oxaliplatin/5FU/LV in the adjuvant treatment of colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years.

    -- A long-term update including disease-free-survival and overall survival

       data from the MOSAIC study, which evaluates the role of

       oxaliplatin/5FU/LV (FOLFOX4) as adjuvant treatment for stage II and III

       colon cancer, will be presented.

    -- Sunday, June 3, 8:15 AM - 8:30 AM, E Arie Crown Theatre, Oral

       Presentation.

Abstract # 4067 - N9741:
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:11/26/2014)... --  Heska Corporation (NASDAQ: HSKA ) - ... advanced veterinary diagnostic and other specialty veterinary products , ... attend The Benchmark Company, LLC,s Micro Cap Discovery Conference on ... at The Palmer House Hilton, 17 E. Monroe Street, ... p.m. Please email hska@haydenir.com or contact your Benchmark ...
(Date:11/26/2014)... Colo. , Nov. 25, 2014 /PRNewswire/ ... ) today announced that its Chief Executive ... at the following upcoming conferences.  The public ... through webcasts on the Array BioPharma website:  ... December 3, 2014Time:1:30 p.m.  Eastern Time Location: ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen (NASDAQ: ... ) today announced that AMAGINE-2 TM , a pivotal, multi-arm ... than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary ... placebo at week 12. Brodalumab 210 mg given every two ... to be superior to Stelara on the primary endpoint of ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... 2, 2011 Omnicell, Inc. (NASDAQ: OMCL ), a ... today announced results for its first quarter ended March 31, 2011. ... quarter of 2011 was $57.2 million as compared with $57.3 ... million or 5.5% from the first quarter 2010 revenue of ...
... (Hologic or the Company) (Nasdaq: HOLX ), a ... imaging systems and surgical products dedicated to serving the healthcare ... fiscal quarter ended March 26, 2011. ... $438.7 million. Net income was $82.4 million, or $0.31 ...
Cached Medicine Technology:Omnicell Announces First Quarter 2011 Results 2Omnicell Announces First Quarter 2011 Results 3Omnicell Announces First Quarter 2011 Results 4Omnicell Announces First Quarter 2011 Results 5Omnicell Announces First Quarter 2011 Results 6Omnicell Announces First Quarter 2011 Results 7Omnicell Announces First Quarter 2011 Results 8Omnicell Announces First Quarter 2011 Results 9Omnicell Announces First Quarter 2011 Results 10Hologic Announces Second Quarter Fiscal 2011 Operating Results 2Hologic Announces Second Quarter Fiscal 2011 Operating Results 3Hologic Announces Second Quarter Fiscal 2011 Operating Results 4Hologic Announces Second Quarter Fiscal 2011 Operating Results 5Hologic Announces Second Quarter Fiscal 2011 Operating Results 6Hologic Announces Second Quarter Fiscal 2011 Operating Results 7Hologic Announces Second Quarter Fiscal 2011 Operating Results 8Hologic Announces Second Quarter Fiscal 2011 Operating Results 9Hologic Announces Second Quarter Fiscal 2011 Operating Results 10Hologic Announces Second Quarter Fiscal 2011 Operating Results 11Hologic Announces Second Quarter Fiscal 2011 Operating Results 12Hologic Announces Second Quarter Fiscal 2011 Operating Results 13Hologic Announces Second Quarter Fiscal 2011 Operating Results 14Hologic Announces Second Quarter Fiscal 2011 Operating Results 15Hologic Announces Second Quarter Fiscal 2011 Operating Results 16Hologic Announces Second Quarter Fiscal 2011 Operating Results 17Hologic Announces Second Quarter Fiscal 2011 Operating Results 18
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used in ... looks and acts similar to asbestos-induced mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Medicine in Hannover injected 500 lab rats with multi-walled ... developed mesothelioma , how quickly it developed appeared ...
(Date:11/26/2014)... November 26, 2014 With a redesign ... Dr. Steven Meier has enhanced the user experience ... and prospective patients an online destination for orthopedic and ... to present the new and improved version of the ... it easier than ever for current and prospective patients ...
(Date:11/26/2014)... IL (PRWEB) November 26, 2014 ... communication management solutions, has been award the ... Magazine. , This award comes as a great ... capabilities within the Lync ecosystem. Specifically, ISI offers ... all modes of Lync communication, including voice, video, ...
(Date:11/26/2014)... For those with a New Year’s resolution ... BODYPUMP™ classes at the University of Colorado Anschutz Health ... looking for. The 45- 60 minute classes have just started ... Center fitness club memberships. , LES MILLS BODYPUMP™ exercise classes ... are aimed at fast results , By focusing on ...
(Date:11/26/2014)... News) -- Youngsters who enter puberty early are at ... Early puberty was linked with a number of factors ... anxiety levels, according to the researchers. Early puberty was ... family and peers, and having friends who were prone ... the study found an association between early puberty and ...
Breaking Medicine News(10 mins):Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2
... finds , WEDNESDAY, June 3 (HealthDay News) -- Crohn,s ... infliximab (Remicade) and azathioprine (Azasan) were more likely to ... who received only one of the drugs, researchers say. ... Week 2009 in Chicago. , Crohn,s disease is an ...
... leads to accurate recommendations for successful treatment of ... patients to avoid more complicated surgery, according to ... Vienna, Vienna, Austria. The study ... MDCT angiography indicated that nine patients should undergo ...
... ... Health Care Delivery and Information Technology Trends , ... Redlands, CA (PRWEB) June 3, 2009 -- Changing global ... Health GIS Conference provides opportunities for health and human services professionals to network ...
... 3 The SSI Group, Inc. (SSI) announced their success ... University Health System (DUHS) and its affiliated hospitals for ... as the primary supplier of claims management products, including but ... the functionality of posting back billing information to the host ...
... the efforts of college students to quit smoking, recent ... suggests that an extended trial and error period is ... in high school, another study by faculty at HEC ... insights into how graphic cigarette warning labels impact intentions ...
... and innovation at Click4Care , , POWELL, Ohio, June ... suite, today announced the appointment of Rob Gillette as CEO. ... next phase of its development, following its explosive growth in ... leading Click4Care, Gillette will continue as CEO of Burlington, Massachusetts-based ...
Cached Medicine News:Health News:Two Drugs Better Than One for Crohn's Patients 2Health News:Two Drugs Better Than One for Crohn's Patients 3Health News:ESRI Health GIS Conference to Feature Speakers Innovating Health Care 2Health News:ESRI Health GIS Conference to Feature Speakers Innovating Health Care 3Health News:ESRI Health GIS Conference to Feature Speakers Innovating Health Care 4Health News:Duke University Health System Chooses SSI for Revenue Cycle Claims Management 2Health News:Duke University Health System Chooses SSI for Revenue Cycle Claims Management 3Health News:Recent smoking-cessation research highlights importance of keeping teens from smoking 2Health News:Click4Care(R) Announces Appointment of Rob Gillette as CEO 2
... patented a new, smaller and faster technology for ... twice the resolution of existing devices. The CardiArc ... runs on 110 Volts AC and fits easily ... The device has no visible moving parts and ...
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... To help cardiologists meet the ... Toshiba introduces the high performance Infinix ... solutions combine easy-to-use controls, one-touch operations, ... to optimize workflow and allow physicians ...
... Right for the typical patient, right for ... Medical ICDs, you have the ability to ... when you least expect themeven after implant. ... you need to be prepared in almost ...
Medicine Products: